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Abstract: Transdermal drug delivery offers a number of advantages including improved 
patient compliance, sustained release, avoidance of gastric irritation, as well as elimination 
of pre-systemic first-pass effect. However, only few medications can be delivered through 
the transdermal route in therapeutic amounts. Microneedles can be used to enhance 
transdermal drug delivery. In this review, different types of microneedles are described and 
their methods of fabrication highlighted. Microneedles can be fabricated in different forms: 
hollow, solid, and dissolving. There are also hydrogel-forming microneedles. A special 
attention is paid to hydrogel-forming microneedles. These are innovative microneedles 
which do not contain drugs but imbibe interstitial fluid to form continuous conduits 
between dermal microcirculation and an attached patch-type reservoir. Several microneedles 
approved by regulatory authorities for clinical use are also examined. The last part of this 
review discusses concerns and challenges regarding microneedle use. 
Keywords: transdermal; microneedles; drug delivery; dissolving microneedles; hydrogel-
forming microneedles 
 
1. Introduction 
Hypodermic needles are used in clinical practice to deliver medications across the skin into the 
bloodstream. Injections with hypodermic needles are important from a clinical standpoint, but painful. 
They may also induce hypersensitivity; bruising, discomfort and bleeding at the site of administration, 
and in some cases are associated with risks of contamination. There are other concerns linked to their 
use including accidental needle stick injury and the necessity to train medical staff regarding the proper 
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use of needles [1]. The difficulty in crossing the skin is caused by its anatomical peculiarities. The skin 
is the largest organ in the body. It is about 1.5 m2 in adults and provides protection for internal  
organs [1]. It also protects the human body against ingress of toxic chemicals and egress of water and 
other essential endogenous substances. Despite the large surface area of the skin, it is challenging for 
compounds including drugs and vaccines to cross the skin in therapeutically relevant amounts. The 
major barrier in the skin is provided by the stratum corneum (SC), which is the outermost layer of the 
skin [2]. The SC is 10–15 μm thick with 15–20 corneocyte layers. It is made up of corneocytes 
embedded in an intercellular lipid matrix. The main lipid classes in human SC are free fatty acids 
(FFAs), ceramides (CERs) and cholesterol which form two lamellar phases. These include the short 
periodicity phase (SPP) and the long periodicity phase (LPP) with repeat distances of approximately  
6 and 13 nm, respectively [3]. Within the lipid lamellae, the lipids are mainly organized in a dense 
orthorhombic packing, although a fraction of lipids adopt a hexagonal packing [4]. Below the stratum 
corneum is the viable epidermis (VE), which is a cellular, avascular tissue measuring 50–100 μm  
thick [5]. The VE consists mainly of keratinocytes and approximately 40% protein, 40% water and  
15%–20% lipids [6]. The undulating epidermal–dermal junction consists of papilla that project into the 
dermis [6]. Cells in the basal layer of the epidermis form the most important structural and functional 
connection to the dermis below [6]. The stratum corneum and viable epidermis together form the full 
epidermis. There is a basement membrane at the base of the epidermis and the existence of tight 
junctions in the viable epidermis has been recently documented. Base membrane and tight junctions 
may both offer resistance to the transport of molecules across the epidermis [5]. Andrews  
et al. recently reported that techniques that only permeabilize stratum corneum are much less effective 
than those that increase the permeability of the entire epidermis [5] The authors showed that  
removal of stratum corneum dramatically increased skin permeability, but removal of the full 
epidermis increased skin permeability by another 1–2 orders of magnitude [5]. The dermis is the 
thickest component of the skin, up to 4 mm in depth. Its upper layer, the 100–200 μm thick papillary 
dermis, consists of thin collagen bundles, elastin fibers, fibrocytes. There is also water, electrolytes, 
plasma proteins and polysaccharides–polypeptide complexes. Below this layer is the reticular dermis, 
made up of thick collagen bundles and coarse elastic fibers [6]. Although the stratum corneum (SC) is 
the major contributor to the barrier properties of the skin, the role of the full epidermis should be taken 
into consideration [5,7]. Only compounds which are able to get into the SC, diffuse through living 
epidermis and pass through the upper part of the papillary dermis has the potential to reach circulation 
and exhibit systemic effects [7]. The dermis contains blood vessels, lymphatics and nerves, as well as 
the various skin appendages. Below the reticular dermis lies the hypodermis (subcutaneous fat tissue), 
which may have a thickness of up to several millimeters. Comprising fat microlobules and fibrous 
collagen, it also contains blood vessels, lymphatics and nerves [6]. 
Microneedles (MN) are currently being utilized to enhance transdermal delivery of small and large 
molecules. With the emergence of microfabrication manufacturing technology over the past several 
decades, MN have been developed by academic laboratories and pharmaceutical companies [8–13]. 
Transdermal MNs create micron sized pores in the skin to enhance delivery of the drug across the  
skin [11,13]. MN are ideal for patient adherence as they do not stimulate nerves that are associated 
with pain. MN improve patient compliance as patient with needle phobia will be more likely to  
apply the patch because of its painlessness [13]. Additionally, patients can administer the drug by 
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themselves [13]. When MN are fabricated in arrays on a backing that can be applied to the skin like a 
bandage, the device is called a MN patch [8]. MN can be divided into four categories (Figure 1): 
hollow, solid, coated and polymer [6]. Hollow MN are like regular hypodermic needles but shorter in 
length. A liquid formulation of the drug is infused through bores in the MN. Solid MN are used to 
create holes in the skin. Subsequently a patch is then applied. Coated MN are MN coated with the drug 
while polymer MN are made from polymers that can be dissolving, nondissolving or hydrogel-forming. 
 
Figure 1. Different types of microneedles: solid, coated, dissolving and hollow (Reprinted 
from [14] with permission. Copyright 2012 Elsevier). 
2. Hollow Microneedles 
Hollow microneedles (HM) can be fabricated from a commercially available 30 gauge hypodermic 
needles [15]. Pressure, and thereby flow rate, can be changed in HM for a rapid bolus injection, a slow 
infusion or a varied delivery rate [14]. HM can also be used to administer a larger dose of drug 
solution [16]. Verbaan et al. fabricated HM from 30G stainless steel needles [15]. The 4 × 4 pattern of 
holes was drilled in a polyetheretherketone mold (diameter 9 mm). Then, the needles were placed 
through the holes at a predetermined length of 300, 550, 700 and 900 μm. Subsequently, the needles 
were cut and glued at the back of the mold. A manual applicator was also designed for the MN  
array [15]. 
Aoyagi et al. fabricated long thin holes with a high aspect ratio of 100 (diameter: 10 μm, depth:  
1 mm) in biodegradable polymer material using a UV excimer laser [17]. Holes having diameters of 
10, 20 and 50 μm were fabricated from the side surface of a polylactic acid (PLA) sheet. The laser 
fabrication approach was then applied to a PLA microneedle, which was fabricated by a micromolding 
technique. A hole was fabricated along the centerline of a microneedle using the above-mentioned 
approach and it was confirmed experimentally that blood plasma was taken into the hole by capillary 
force [17]. 
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There is also a report in the literature on a novel method for fabricating HM using a composite of 
vertically-aligned carbon nanotubes and polyimide [18]. Patterned bundles of carbon nanotubes were 
used as a porous scaffold for defining the MN geometry. Polyimide resin was then wicked through the 
carbon nanotube scaffold to reinforce the structure and provide the required mechanical strength for 
achieving skin penetration. The high aspect ratio and bottom-up assembly of carbon nanotubes makes 
it possible to create MN in a single step of nanotube fabrication [18]. 
For HM, it is important that adequate and constant flow rate is maintained for transdermal drug 
delivery, without compromising the mechanical strength of the needles. The main factor affecting the 
flow rate is the compression of the dense dermal tissue at the needle tip during insertion [19]. 
Sometimes, it is advantageous to have very sharp MN with the bore of the MN offcentered or on the 
side of the microneedle. Increasing microneedle bore may increase the flow rate; however, this results 
in a decreased MN strength and a reduction in sharpness. Another way to increase the MN strength is 
by applying a metal coating on the MN. However, this may decrease MN sharpness [19]. Hollow  
out-of-plane silicon microneedles were fabricated. A sequence of deep-reactive ion etching (DRIE), 
anisotropic wet etching and conformal thin film deposition was used. Tip curvature was defined by 
lithography and the length of the needles varied between 150 and 350 micrometers [20]. To fabricate 
hollow microneedles, Pérennès first fabricated a master through a double deep X-ray lithography 
process [21]. First, a polymethylmethacrylate (PMMA) sheet was exposed to produce single PMMA 
parts with a sawtooth profile. The tip angle of each tooth determined the final tip angle of the 
microneedles. The PMMA parts were then assembled and glued on a conductive substrate and  
then exposed through a second X-ray mask containing an array of hollow triangles as absorbing  
structures [21]. A metal layer was then electrodeposited around the needles in order to form the future 
base of the array. A polyvinyl alcohol (PVA) solution was cast on top of the master to form a negative 
mold of the MN array after low temperature curing and peel-off steps. A liquid PMMA solution was 
then cast on top of the PVA negative mold and after the full PMMA polymerization, the PVA was 
dissolved in water [21]. 
Silicon MN are justified by their mechanical properties and their biocompatibility potential. 
However inconveniences such as high production costs or fragility have spurred researchers to look for 
other options [1]. 
Hollow silicon MN were fabricated by using isotropic etching followed by anisotropic etching to 
obtain a tapered tip [22]. Silicon MN of 300 μm in height, with 130 μm outer diameter and 110 μm 
inner diameter at the tip followed by 80 μm inner diameter and 160 μm outer diameter at the base  
were fabricated using this technique. In order to improve the biocompatibility of MN, the fabricated 
microneedles were coated with titanium (500 nm) by sputtering technique followed by gold coating 
using electroplating. A breaking force of 225 N was obtained for the fabricated MN, which is 10 times 
higher than the skin resistive force. 
Hollow microneedles can also be fabricated using other micro-electro-mechanical systems (MEMS) 
technologies such as laser micromachining, deep reactive ion etching, integrated lithographic molding 
technique, wet chemical etching and X-ray photolithography [14]. 
AdminPen® MN have also been fabricated [17]. These are hollow stainless steel MN of varying 
lengths from 600 to 1500 µm, which can be connected to a syringe and used to deliver liquid 
formulations. AdminStamp® devices contain AdminPatch® microneedle arrays attached to an 
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applicator with six stainless steel screws. They can also be used to porate the skin without any liquid. 
When used in this way, they are like solid MN because they first create the holes before a drug 
solution is applied. 
Hollow microneedles can deposit a compound directly into the viable epidermis or the dermis 
avoiding the stratum corneum. This is especially useful for the delivery of high molecular weight 
compounds such as proteins, oligonucleotides and vaccines. Transdermal delivery of insulin continues 
to represent a significant scientific challenge. Cheung et al. used 1100 and 1400 µm long stainless steel 
microneedles to deliver insulin across porcine skin [12]. Two commercial MN patches, namely, 
AdminPatch Array 1200 MN and AdminPatch Array 1500 MN array (AdminMed, Sunnyvale, CA, 
USA) were used to pretreat the pig skin. The authors investigated the effect of insertion force and 
found out that when porcine skin was pretreated with an applied force of 60.5 and 69.1 N, the resultant 
amount of insulin permeated was approximately 3 and 25 µg over a four-hour period [12]. 
A hollow microneedle was used by Jun et al. to deliver a phenylephrine (PE) solution into the anal 
sphincter muscle as a method for treating fecal incontinence [23]. The goal of the study was the local 
targeted delivery of phenylephrine into the sphincter muscle through the perianal skin with minimal 
pain, resulting in the increase of resting anal sphincter pressure. PE was administered on the left and 
the right sides of the anus of a rat through the perianal skin using 1.5 mm long hollow microneedle [23]. 
Specific and effective gene silencing of certain diseases can be achieved by an accurate knowledge 
of the target mRNA sequence and rational design of its complementary antisense agents for protein 
downregulation. Antisense technology uses agents like antisense oligonucleotides, ribozymes, short 
interfering RNA (siRNA), microRNA (miRNA), apatamers, and others to manipulate gene expression 
and treat various pathological disorders [24]. Luo et al. used a combination of microneedle (MN) 
arrays and biochemical approaches for localized intratissue delivery of oligonucleotides in three-
dimensional tissue models [25]. This approach is applicable to transdermal drug delivery. 
It is desirable that hollow microneedles possess adequate mechanical strength and that the bores are 
not clogged during transdermal drug delivery. Even though, a number of fabrication techniques have 
been highlighted earlier, there is a need to continue research that will lead to a “gold standard” hollow 
microneedle drug delivery system. 
3. Solid Microneedles 
Solid MN (Figure 2) deliver drugs via passive diffusion by creating microchannels to increase skin 
permeability followed by the application of a drug-loaded patch on the channels [26]. From a safety 
perspective, it is desirable for the microchannels to close soon after needle removal to prevent 
permeation of undesired toxic substances or infection by pathogenic microorganisms [26]. Henry et al. 
used a deep reactive ion etching process to fabricate silicon MN [27]. A chromium masking material 
was first deposited onto silicon wafers and patterned into dots which had a diameter approximately 
equal to the base of the desired microneedles. The wafers were then loaded into a reactive ion etcher 
and subjected to plasma etching. The regions protected by the metal mask remained to form the 
microneedles [27]. Vinayakumar et al. fabricated an array of rectangular cup shaped silicon 
microneedles [28]. These microneedles have the potential for reduced drug leakage resulting in 
improvement of drug delivery efficiency and the possibility of introducing multiple drugs [28]. The 
Pharmaceutics 2015, 7 95 
 
 
fabricated solid MN with rectangular cup shaped tip are 200 μm in height [28]. The cup shaped tips 
have dimensions of 60 × 60 μm (length × breadth) with a depth of 60 μm. The cups are filled with drug 
using a novel drop coating system [28]. Gupta fabricated stainless steel solid MN by laser cutting 
stainless steel sheets [26]. The desired microneedle shape and dimensions were first drafted in 
AutoCAD software [29]. Infrared laser was operated at 1000 Hz, 20 J/cm2 energy density and 40% 
attenuation of laser energy to cut the microneedles. A total of three passes were required to completely 
cut through the stainless steel sheet. MN were either prepared as individual rows of needles (“in-plane” 
needles) or as two-dimensional arrays of needles cut into the plane of the stainless steel sheet and 
subsequently bent at 90° out of the plane (“out-of-plane” needles) [29]. The stainless steel MN arrays 
were manually cleaned with detergent. To prepare “out-of-plane” MN, stainless steel MN were first 
manually pushed out of the sheet using either forceps or a hypodermic needle and then bent at 90° 
angle with the aid of a single-edged razor blade. Stainless steel microneedles can also be made by  
wet-etching photolithographically defined needle structures from stainless steel sheets [30]. The authors 
used these MN to deliver a vaccine based on virus-like particles containing influenza virus heterologous 
M2 extracellular (M2e) domains (M2e5xVLPs). 
 
Figure 2. Solid microneedles fabricated from silicon, metal and polymer (Reprinted  
from [14] with permission. Copyright 2012 Elsevier). 
Solid MN can be fabricated from polymers. Olatunji et al. prepared MN from biopolymer films 
extracted from fish scales of tilapia (Oreochromiss sp.) using micromolding technique. The MN were 
successfully inserted into porcine skin and were shown to dissolve gradually at 0, 60, 120 and 180 s 
after insertion [31]. The microneedles contained methylene blue as model drug and successfully 
pierced porcine skin [31]. 
A microneedle roller is a device that contains MN mounted on cylindrical surface that rolls over the 
skin [6]. In this scenario, MN are mounted on a cylindrical surface and can be rolled across the skin, 
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such that each microneedle may pierce the skin multiple times as the roller rotates across the skin [23]. 
In our laboratory, we studied the transdermal delivery of verapamil hydrochloride and amlodipine 
besylate using MN rollers and stainless steel MN. Adminpatch stainless steel microneedle arrays 
manufactured by NanoBioSciences™ were also used in these experiments. In vitro studies were 
performed with microneedle-treated porcine ear skin using vertical static Franz diffusion cells. Passive 
diffusion across untreated porcine skin served as control. Aliquots were taken every two hours for 12 h 
and analyzed by liquid chromatography–mass spectrometry. Transcutaneous flux of verapamil increased 
significantly from 8.75 to 49.96 µg/cm2/h across microneedle-roller treated porcine skin [13]. 
Percutaneous flux of amlodipine besylate following the use of stainless steel microneedles was  
22.39 µg/cm2/h. Passive flux for the drug was 1.57 µg/cm2/h. This enhancement of amlodipine flux 
was statistically significant. Transdermal flux of amlodipine with MN roller was 1.05 µg/cm2/h in 
comparison with passive flux of 0.19 µg/cm2/h. The difference in flux values was also statistically 
significant [13]. 
In another study, we used stainless steel microneedle arrays (750 μm) made by Microneedle 
Systems® to facilitate the delivery of captopril and metoprolol tartrate across porcine skin. We studied 
the influence of MN rollers on the diffusion of these drugs [32]. In vitro diffusion studies were carried 
out using vertical Franz diffusion cells. Transdermal flux values for captopril and metoprolol tartrate 
increased from 75.04 to 608.2 μg/cm2/h and 62.28 to 290.93 μg/cm2/h respectively following the  
use of microneedle arrays [32]. Transcutaneous flux for captopril increased from 19.68 to  
1485.20 μg/cm2/h, whereas metoprolol tartrate flux increased from 84.64 to 226.08 μg/cm2/h after 
treatment of pig skin with microneedle rollers. There was statistically significant enhancement in 
transdermal flux (p < 0.05) of captopril and metoprolol tartrate after application of microneedle arrays 
and rollers [32]. 
Nalluri et al. studied the influence of AdminPatch® microneedle arrays (MN) (0.6, 0.9, 1.2 and  
1.5 mm lengths) and Dermaroller® microneedle rollers (DR) (0.5 and 1 mm lengths) on transdermal 
permeation of sumatriptan [33]. A significant increase in cumulative amount of sumatriptan (SMT) 
permeated, steady state flux, permeability coefficient and diffusion coefficient values were observed 
after microneedle treatment, and the values were in the order of 1.5 mm MN > 1.2 mm MN > 0.9 mm 
MN > 1 mm DR > 0.6 mm MN > 0.5 mm DR > passive permeation [33]. Lag times were significantly 
shorter after longer microneedle application (0.24 h for 1.5 mm MN). Arrays were found to be superior 
to rollers with similar microneedle lengths in enhancing SMT permeation. The authors attributed this 
higher flux enhancement to higher density of microneedles and force of application onto skin. The  
in vitro flux values revealed that a 2.5 cm2 patch was adequate for effective therapy after treatment of 
skin with 1.5 mm MN. 
Solid MN are also promising for the delivery of vaccines. Microneedle-mediated delivery of 
vaccines can lead to longer-lasting and more-robust antibody responses in comparison with 
intramuscular delivery [8]. Ultimately, this leads to improved vaccine efficacy. MN patches contain 
micron-scale (<1000 µm) solid needles containing a dry formulation of a vaccine that rapidly dissolves 
upon patch application [34]. A population immunity of approximately 93%–95% is required to 
interrupt measles virus transmission due to the virulence of the measles virus [34]. Edens used 
dissolving MN to delivery 1000 tissue culture infectious dose (TCID50) of measles vaccine [34]. The 
MN patch contained 100 pyramidal MN, each measuring 600 µm long, 300 µm wide at the base and 
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tapering to a tip radius of less than 3 µm [34]. Following the use of this MN patch, all of the animals 
sero-converted and had a titer of >120 mIU/mL, which is considered protective in humans [34]. 
4. Dissolving Microneedles 
Interest in dissolving microneedles is high because of a number of advantages. These include the 
one-step application process which is convenient for patients. Dissolving MN are fabricated on the 
basis of the “poke and release” principle. They are made from polysaccharides or other polymers. 
These MN release encapsulated drug into the skin following application and dissolution. 
Micromoulding is the preferred fabrication method for making dissolving MN. Certain drugs and 
vaccines are thermolabile so moulds are often filled with solutions of drugs and excipients and then 
dried under mild conditions. The fabrication process involves pouring the polymer solution into  
female molds, filling the microcavities of the mould under vacuum or pressure, drying under ambient 
conditions, centrifugation or pressure [35–37]. 
Master structures for MN supporting arrays, and pressing tools were created by Chen et al. using 
proprietary electro-discharge-machining technology [38]. Each master structure consisted of 64 (8 × 8) 
microstructures. Polydimethylsiloxane (PDMS) molds were created as exact inverse-replicates of the 
master structures. To prevent adhesion to PDMS molds, all master structures were sputter-coated with 
platinum [38]. PDMS molds were fabricated by pouring PDMS solution over the master structure and 
allowing the polymer to cure overnight at room temperature. The cured PDMS molds were then peeled 
from the master structures and used to make the chitosan microneedles, polylactic acid supporting 
arrays, and polycaprolactone pressing tools [38]. 
Thermal drawing is a commonly used prototyping method that can be used to make microneedle 
(MN) structures with ultra-high aspect ratio. However, it is difficult to repeatedly produce MNs with 
identical shapes using thermal drawing due to fluctuations in temperatures, drawing speeds or drawing 
heights [39]. Lee et al. fabricated master molds by thermal drawing and replicated high aspect ratio 
silk fibroin microneedles from these master molds multiple times [39]. The authors used poly(lactic-
co-glycolic acid) to fabricate MN masters for micromolding. A spatially-discrete thermal drawing 
system was used to fabricate PLGA MN masters. Polydimethylsiloxane was used with the mixing ratio 
of 10:1 between silicone elastomeric base and curing agent to fabricate negative molds from the PLGA 
masters [39]. An aqueous silk fibroin (SF) solution from Bombyx mori silk worm cocoon was used to 
make the microneedles. To fabricate MN-shaped negative molds, PDMS resin was poured on the 
PLGA MN masters and cured at a room temperature for 24 h. After curing, negative PDMS molds 
were prepared. Finally, an aqueous SF solution was poured on the negative PDMS molds and degassed 
several times by application of vacuum conditions followed by drying at room temperature for 24 h. 
Liu et al. fabricated hyaluronic acid (HA) microneedles using micromoulding [40]. Blue dye or 
fluorescein isothiocyanate-labeled dextran (4 kD; FD4) solution was added to 15% HA solution. HA 
solution containing blue dye or FD4 was placed on a micromould at room temperature. After drying 
for 2 h in desiccator, a polyethylene terephthalate (PET) adhesive tape was attached on the base plate 
for reinforcing, then 20% HA solution was placed on the PET. After drying completely, a sheet of 
microneedle arrays containing blue dye or FD4 was obtained by peeling the mold off [40]. The authors 
showed that the cumulative permeated amount of FD4 significantly increased across the skin after the 
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application of HA microneedle arrays compared to a solution over a period of 7 h. The cumulative 
permeated amount of FD4 in solution was low, with a value of 0.38 ± 0.20 µg/cm2. In contrast, the 
cumulative permeated amount of FD4 increased significantly after application of microneedle arrays 
with a value of 231.80 ± 28.76 μg/cm2 over the same period. The authors observed almost no lag time 
in drug permeation when microneedle arrays were used [40]. 
An interesting and useful approach is the use of near-infrared (NIR) light-responsive polymer-
nanostructure composite microneedles used for on-demand transdermal drug delivery [41]. Silica-
coated lanthanum hexaboride (LaB6@SiO2) nanostructures were incorporated into polycaprolactone 
microneedles, serving as a near infrared ray absorber absorber [41]. When the microneedles were 
irradiated with NIR light, light-to-heat transduction mediated by the LaB6@SiO2 nanostructures caused 
the microneedle to melt at 50 °C [41].The advantage of this approach is that the release of active 
pharmaceutical ingredients can be triggered externally using near infrared rays. 
Chen et al. also prepared a microneedle transdermal delivery system, composed of embeddable 
chitosan microneedles and a poly(L-lactide-co-D,L-lactide) (PLA) supporting array and used the 
microneedles for complete and sustained delivery of encapsulated antigens to the skin [38]. Chitosan 
microneedles were mounted to the top of a strong PLA supporting array, providing mechanical 
strength to fully insert the microneedles into the skin. When inserted into rat skin in vivo, chitosan 
microneedles successfully separated from the supporting array and were left within the skin for 
sustained drug delivery without requiring a transdermal patch [38]. 
Transdermal delivery of insulin is still a considerable challenge in the scientific community due to 
the low permeation rate of the drug across the skin and the difficulty of achieving therapeutic 
concentration with this mode of administration. Chen et al. combined nanovesicles with iontophoresis 
and used these techniques to drive insulin across microneedle-treated pig skin [42]. The penetration 
rate of insulin from nanovesicles driven by iontophoresis through skin with microneedle-induced 
microchannels was 713.3 times higher than that of its passive diffusion [42]. 
DNA vaccinations rely mainly on cellular delivery of plasmid DNA to induce expression of an 
encoded antigen, and thus lack of a proper delivery system for DNA vaccines is considered to be one 
of reasons for their low level of immunity [43]. A polyplex is a complex of a polymer and DNA, which 
is designed to protect the DNA during delivery. DNA polyplexes are efficiently protected from 
enzymatic degradation and exhibit increased cell transfection efficiency. MNs coated with naked DNA 
vaccines can induce significant antibody- and cell-mediated immune responses, thereby providing 
protective immunity. Kim et al. used microneedle arrays coated with a pH-responsive polyelectrolyte 
multilayer assembly (PMA) to deliver polyplex-based DNA vaccines [43]. 
Pearton et al. used coated microneedles to delivery plasmid DNA [44]. Optimization of a  
dip-coating method enabled significant increases in the loading capacity, up to 100 μg of plasmid DNA 
(pDNA) per 5-microneedle array. Coated microneedles were able to reproducibly perforate human  
skin at low (less than 1N) insertion forces [44]. The physical stability of the coated pDNA was 
partially compromised on storage, although this was improved through the addition of saccharide 
excipients without detriment to the biological functionality of pDNA. The pDNA-coated microneedles 
facilitated reporter gene expression in viable human skin [44]. 
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5. Coated Microneedles 
Coated microneedles refer to microneedles which are coated with the drug-containing dispersion.  
A plethora of techniques has been used in the literature to prepare coated microneedles. An approach 
using electrohydrodynamic atomisation (EHDA) principles in the preparation of smart microneedle 
coatings was reported in the literature [45]. Stainless steel (600–900 µm in height) microneedles were 
coupled to a ground electrode (in the EHDA coating set-up) with the deposition distance and collecting 
methodology varied for an ethanol:methanol (50:50) vehicle system. The authors used this technique 
to prepare nano- and micrometer-scaled pharmaceutical coatings [45]. Fluorescein dye (serving as 
potential drug, sensory materials or disease state markers) and polyvinylpyrrolidone (PVP, polymer 
matrix system) formed the remaining components of the coating formulation. Based on these 
excipients and by varying the coating process, particles (100 nm to 3 µm) and fibres (400 nm to 1 µm) 
were deposited directly on MNs in controlled and selectable fashion [45]. 
Ma and Gill used a polyethylene glycol matrix containing a water insoluble drug lidocaine to coat 
solid microneedles [46]. Uniform coatings were obtained on microneedle surfaces. In vitro dissolution 
studies in porcine skin showed that microneedles coated with PEG-lidocaine dispersions resulted in 
significantly higher delivery of lidocaine in just 3 min compared with 1 h topical application of 0.15 g 
EMLA®, a commercial lidocaine-prilocaine cream [46]. 
6. Hydrogel-Forming Microneedles 
The first two microneedle-based products, just recently marketed, Soluvia® and Micronjet®, are 
based on metal and silicon, respectively [47]. However, the current trend in microneedle-based 
research has recognized biocompatibility problems associated with the use of silicon and the potential 
for inappropriate re-use of silicon or metal microneedles, which remain fully intact after removal from 
a patient’s skin. This has led to a multiplicity of technologies aimed at overcoming this shortcoming. 
In this regard, recent effort has focused on microneedles formulated from aqueous polymer gels. One 
of these approaches involves the use of hydrogel-forming microneedles [47]. One of the differences 
and advantages in comparison with regular dissolving polymer microneedles is that by using this drug 
delivery system, delivered doses of drugs and biomolecules are no longer limited to what can be 
loaded into the needles themselves. 
Donnelly et al. prepared hydrogel-forming microneedles from “super-swelling” polymeric 
compositions. These are microneedle arrays, prepared under ambient conditions, which contain no 
drug themselves [48]. Instead, they rapidly imbibe skin interstitial fluid upon insertion to form 
continuous conduits between the dermal microcirculation and an attached patch-type drug reservoir [48]. 
Such microneedles act initially as a tool to penetrate the stratum corneum barrier. Upon swelling, they 
become a rate controlling membrane. Fluid uptake range in one hour was 0.9–2.7 μL which is of  
the same order of magnitude as the rates of interstitial fluid uptake for hollow microneedles and 
microdialysis [49]. Other advantages of hydrogel-forming microneedles are that they can be fabricated 
in a wide range of patch sizes and geometries, can be easily sterilized, resist hole closure while in place 
and are removed completely intact from the skin [50]. While these systems may work for  
high-potency, low dose drugs and vaccines, there is a need to broaden their application to include 
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medications that are administered for the management of chronic disorders. Recently, there was a 
report on the investigation of various polymeric compositions in order to find materials capable of 
rapid swelling, but which would be sufficiently hard in the dry state to penetrate the skin. These materials, 
once swollen, should maintain structural integrity and be reasonably robust during handling [48]. Stock 
solutions of Gantrez S-97 (40% w/w) or AN-139 (30% w/w) were prepared using deionized water. 
Hydrogel films were then prepared using varying concentrations of the co-polymer, PEG 10,000 and 
the modifying agent, sodium carbonate. Films were cured at 80 °C for 24 h to induce chemical 
crosslinking between the PMVE/MA and PEG by ester formation. Swelling studies were conducted 
and the results used to select optimal polymeric compositions [48]. A microneedle formulation with 
enhanced swelling capabilities from aqueous blends containing 20% w/w Gantrez S-97, 7.5% w/w PEG 
10,000 and 3% w/w Na2CO3 and using a drug reservoir of a lyophilized wafer-like design was selected. 
These microneedle-lyophilised wafer compositions were robust and effectively penetrated skin, 
swelling extensively, but they were removed intact [48]. Significantly, in vitro delivery experiments 
across excised neonatal porcine skin showed that approximately 44 mg of the model high dose small 
molecule drug ibuprofen sodium was delivered in 24 h, equating to 37% of the loading in the 
lyophilised reservoir. The super swelling microneedles delivered approximately 1.24 mg of the model 
protein ovalbumin over 24 h, equivalent to a delivery efficiency of approximately 49% [48]. Silicon 
MN arrays to be used as master templates in micromoulding of hydrogel-forming arrays were first 
microfabricated. Using the above silicon MN arrays as master templates, silicone elastomer 
micromoulds were then prepared. The authors fabricated microneedles with enhanced swelling 
capabilities from aqueous blends containing 20% w/w Gantrez S-97, 7.5% w/w PEG 10,000 and  
3% w/w Na2CO3 and utilized a drug reservoir of a lyophilized wafer-like design. In in vitro delivery 
experiments across excised neonatal porcine skin, approximately 44 mg of ibuprofen sodium was 
delivered in 24 h, equating to 37% of the loading in the lyophilized reservoir. The hydrogel-forming 
microneedles also delivered approximately 1.24 mg of the model protein ovalbumin over 24 h, 
equivalent to a delivery efficiency of approximately 49% [48]. 
In a recent report, investigators incorporated caffeine and lidocaine hydrochloride into transdermal 
microneedle systems using novel laser-engineered polymers. Potential pediatric applications were 
studied [51]. The authors prepared adhesive patches using aqueous blends consisting of 10% w/w 
PMVE/MA and 5% w/w tripropyleneglycol methyl ether [51]. Facilitated transdermal transport of 
caffeine and lidocaine HCl were observed using drug-loaded dissolving MN and integrated hydrogel-
forming MN in comparison to their corresponding control patches/cream across dermatomed skin over 
a period of 24 h [51]. 
The use of hydrogel-forming MN is promising. Indeed more effort should be directed at widening 
the range of materials that can be used to fabricate these useful transdermal drug delivery systems. 
Although hydrogel-forming MN are made from polymers, there are distinct differences between the 
two groups of MN. The possibility of incorporating active pharmaceutical ingredients in a separate 
reservoir means that it is possible to increase the amount of delivered medications. 
Pharmaceutics 2015, 7 101 
 
 
7. Clinical Trials 
In 2009, a six-month, randomized, multicenter, blinded, multi-dose, Phase 2 clinical study using 
MN to deliver recombinant human parathyroid hormone 1-34, teriparatide (PTH, 4.1 kDa) was carried 
out [52]. The study demonstrated that 40 µg of PTH delivered using solid titanium MN was capable of 
delivering an effective amount of PTH, comparable to a 20 µg of Forteo (PTH) injection. Zosano 
Pharma Corporation has developed ZP-PTH which is a transdermal MN formulation of parathyroid 
hormone 1-34 (PTH) [52,53]. The product has completed Phase 2 clinical trials and is scheduled for 
Phase III trials. If approved, it will be used for the management of osteoporosis. The product is  
based on titanium microneedle arrays produced by photochemical etching. The MN come with a 
reusable applicator. NanoPass Technologies also has an intellectual property-backed product called 
MicronJet™ [52]. It is a single use, microneedle-based device for intradermal delivery of drugs, 
proteins and vaccines. 
8. Challenges 
There is a tremendous amount of research being carried out to study the influence of MN on 
transdermal drug delivery. There is immense potential for the use of these micron-sized needles for 
transdermal drug delivery enhancement. However, for these needles to find widespread clinical 
applications, a number of challenges also have to be addressed including irritation, microbial 
contamination and the delivery of therapeutically relevant concentrations of drugs. There is also a 
limited choice of appropriate biomaterials, lack of mechanical strength, poor control of drug delivery, 
and limitation of drug loading dose [39]. Potent drugs requiring low doses and vaccines seem to be the 
drugs most likely to be delivered in therapeutically useful concentrations. Another challenge is the 
delivery of macromolecules- products of biotechnology. These molecules have high molecular weights 
and also high hydrophilicity making them particularly challenging to deliver across the skin. There is 
also the concern that some MN such as those fabricated from silicon and some polymers may not have 
adequate mechanical strength to pierce the skin. The ideal scenario is to fabricate MN with a low 
insertion force and a high fracture force. It is also cumbersome for MN to be applied in a two-step 
manner, that is to porate the skin first and then apply a patch. In this regard, the use of  
hydrogel-forming microneedles is particularly interesting. There is also the need to balance penetration 
enhancement with painlessness. 
9. Conclusions 
This paper has described some of the landmark achievements in MN fabrication and applications. 
Several important milestones have been achieved through the use of micro-electro-mechanical systems 
(MEMS) technologies and those developed specifically to optimize MN for transdermal drug delivery. 
Valid concerns regarding the use of these MN especially safety issues have also been highlighted. 
There are concerns about delayed onset of action, costs of the delivery system, possible accidental use, 
misuse or abuse [51]. There is a need to investigate further skin pore closure after MN application 
especially as it relates to the risk of infections. It is also essential to ensure that materials which are 
used for MN fabrication do not induce skin irritation. Another area is the need for a balance between 
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increased permeability and painlessness. It is known that as MN length increases, there is a high 
probability that pain receptors located in the dermis may be stimulated. In spite of the  
above-mentioned limitations, the outlook for the use of these devices is promising even as more work 
needs to be done for microneedles to become routine drug delivery systems in clinical practice. 
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